RXRX vs BIIB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 27, 2026

RXRX

47.4
AI Score
VS
RXRX Wins

BIIB

34.4
AI Score

Investment Advisor Scores

RXRX

47score
Recommendation
HOLD

BIIB

34score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric RXRX BIIB Winner
Forward P/E 0 13.245 Tie
PEG Ratio 0 2.2266 Tie
Revenue Growth -60.1% 3.4% BIIB
Earnings Growth 0.0% -84.8% RXRX
Tradestie Score 47.4/100 34.4/100 RXRX
Profit Margin 0.0% 8.3% BIIB
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY RXRX

Relative Price Performance (Last 90 Days)

RXRX 1M: +1.6% · 3M: +24.6% BIIB 1M: +10.8% · 3M: +22.7%

Current Technical Phase

RXRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (10.3% over 20 days), RSI 50

RSI (14): 50.1 · Price: $3.80

BIIB

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (5.1% over 20 days), RSI 72

RSI (14): 71.6 · Price: $252.26

Fundamentals Snapshot

Metric RXRX BIIB
Market Cap — —
Forward P/E -4.4 15.3
Trailing P/E — 44.5
Revenue (TTM) — —
Revenue Growth -0.6% 0.0%
Gross Margin -7.2% 0.8%
Operating Margin -17.6% 0.3%
EPS -1.00 5.63
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RXRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.